Riskpilot← Back to searchSign inGet full accessADENIUM BIOTECH ApS
APSIn liquidationCVR 33882785Ole Maaløes Vej 3Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 20111 employees
Revenue 2019
DKK -2,9M
EBITDA margin
136.5%
+25% vs 2018
Equity ratio
-48.4%
Financial strength
Net profit 2019
DKK -3,5M
+24% vs 2018
| Revenue | DKK -2,9M | — |
| EBITDA | DKK -4M | +25% |
| Net profit | DKK -3,5M | +24% |
| Total assets | DKK 3,3M | -55% |
| Equity | DKK -1,6M | -182% |
| Employees | 1 | — |
Legal name
ADENIUM BIOTECH ApS
CVR number
33882785
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
2. september 2011
Share capital
DKK 3.773.506
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -11.534 | — | 980 | — | — | — | — | -2.898 |
| Staff expenses | -0 | -2.321 | -4.106 | -3.236 | -2.957 | -4.638 | -2.854 | -1.057 |
| EBITDA | -12.069 | -11.092 | -15.936 | -27.803 | -14.831 | -11.568 | -5.242 | -3.955 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -18 | -18 | -18 |
| EBIT | -12.069 | -11.092 | -15.936 | -27.803 | -14.831 | -11.587 | -5.260 | -3.974 |
| Net financials | 0 | 0 | -50 | -1.675 | -3.660 | -3.110 | -161 | -343 |
| Profit before tax | -12.069 | -11.092 | -15.986 | -29.478 | -18.491 | -14.697 | -5.422 | -4.317 |
| Tax | -2.509 | -1.250 | -3.566 | -5.875 | -3.017 | -2.185 | -820 | -812 |
| Net profit | -9.561 | -9.842 | -12.419 | -23.603 | -15.474 | -12.512 | -4.602 | -3.505 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 10.671 | 14.384 | 17.407 | 19.198 | 19.144 | 8.160 | 7.295 | 3.255 |
| Equity | 9.963 | 12.120 | -299 | -23.901 | -39.375 | 6.531 | 1.929 | -1.576 |
| Long-term debt | 708 | 0 | 12.043 | 37.711 | 55.650 | 0 | 0 | 4.478 |
| Short-term debt | 0 | 2.263 | 5.663 | 5.388 | 2.870 | 1.630 | 5.366 | 354 |
| Total debt | 708 | 2.263 | 17.706 | 43.099 | 58.520 | 1.630 | 5.366 | 4.832 |
EBITDA margin
-395536600.0%
This company
15.8%
Market median
-2503396303% vs market
20122019
Equity ratio
-48.4%
This company
38.2%
Market median
-227% vs market
20122019
Return on equity
-350494100.0%
This company
18.4%
Market median
-1904859339% vs market
20122019
Net profit margin
-350494100.0%
This company
8.1%
Market median
-4327087754% vs market
20122019
Asset turnover
-0.89×
This company
1.12×
Market median
-179% vs market
20122019
Debt / equity
3.07×
This company
0.62×
Market median
-395% vs market
20122019
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PH Management | Management | 2011 | — | — |
SS Unofficial title | Unofficial title | 2019 | — | — |
TV Management | Management | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2012 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2012 | — | — | |
| Chairman | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
SUNSTONE LIFE SCIENCE VENTURES FUND III K/S | Company | 33.3% | 33.3% | 2013 |
Novo Holdings A/S | Company | 33.3% | 33.3% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ADENIUM BIOTECH ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Hviid Nordkild | Management | 0 companies |
| Søren Sylvester Skjærbæk | Unofficial title | 0 companies |
| Torgeir Vaage | Management | 0 companies |
| Ejner Bech Jensen | Board of Directors | 0 companies |
| Kristian Merser | Board of Directors | 0 companies |
| Emmanuelle Coutanceau | Board of Directors | 0 companies |
| Casper Tind Hansen | Board of Directors | 0 companies |
| Joseph Michael Feczko | Board of Directors | 0 companies |
| James Peter Arthur Benson | Board of Directors | 0 companies |
| Stephan Christgau | Board of Directors | 0 companies |
| Khalid Islam | Chairman | 0 companies |
| John Howard Rex | Board of Directors | 0 companies |
| Anker Gunvald Lundemose | Board of Directors | 0 companies |
| Andreas Rutger Segerros | Board of Directors | 0 companies |
| Paul David Goldenheim | Chairman | 0 companies |